...dystrophy (DMD), with a reduction in cardiac fibrosis as one of the trial's secondary endpoints. VentriNova Inc....
...FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. HaYa Therapeutics, Waadt, Switzerland University of Lausanne, Lausanne, Switzerland VentriNova Inc....
...novel heart-specific long non-coding RNAs." European Heart Journal (2014) Mark Zipkin, Staff Writer FG-3019 FibroGen Inc. HaYa Therapeutics University of Lausanne VentriNova Inc. Cyclin...

...of companies - including Taxus Cardium Pharmaceuticals Group Inc. (OTCQB:CRXM), ViroMed Co. Ltd. (KOSDAQ:084990) and VentriNova Inc....

...the Icahn School of Medicine at Mount Sinai . Chaudhry also is the founder of VentriNova Inc....
...Angeles , Calif. University of Paris-Sud , Paris, France University of Strasbourg , Strasbourg, France VentriNova Inc....

...therapy increased the number of actively dividing cardiomyocytes compared with empty vector. Planned work by VentriNova Inc....
...4). SciBX 7(9); doi:10.1038/scibx.2014.256 Published online March 6, 2014 Patented by Columbia University; licensed to VentriNova...

...heart function in pig models of myocardial infarction. 1 The technology has been licensed to VentriNova Inc....
...important question in cardiovascular medicine: can we get cardiomyocytes to divide?" said Chaudhry, who founded VentriNova...
...into cardiomyocytes, she said. Chaudhry said that VN-100 -in pig models of MI this year. VentriNova...